$55M Series D Boosts Drug Farm’s AI-Driven Clinical Pipeline
Event summary
- $55M Series D co-led by Shanghai Pudong Leading Area Investment Center and Shanghai Puxing Collaborative Private Equity Fund
- Proceeds to advance DF-003 (Phase 3 trial for ROSAH syndrome) and DF-006 (hepatitis B clinical development)
- AI-driven platforms IDInVivo+ and MedChem5 powering drug discovery and validation
- DF-003 first AI-developed drug entering Phase 3, with Fast Track and Orphan Drug designations from FDA
The big picture
Drug Farm’s $55M Series D underscores investor confidence in AI-powered drug discovery, particularly for rare and metabolic diseases. The financing positions the company to compete with larger biotechs in accelerating clinical trials while maintaining proprietary control over its target-identification platforms. The focus on ROSAH syndrome and hepatitis B aligns with growing interest in precision therapies for underserved patient populations.
What we're watching
- Clinical Milestones
- The pace at which DF-003 advances through Phase 3 for ROSAH syndrome and achieves clinical proof of concept in atherosclerotic cardiovascular disease.
- Pipeline Expansion
- Whether Drug Farm can sustain its AI-driven discovery engine to deliver additional first-in-class candidates into the clinic.
- Regulatory Strategy
- How Drug Farm leverages FDA designations (Fast Track, Orphan Drug) to accelerate DF-003’s path to market.
Related topics